PDCD1 and hepatocellular carcinoma: A recent study revealed that fecal samples of unresectable hepatocellular carcinoma (HCC) patients with objective clinical responses following treatment with anti-PD-1 agents (nivolumab or pembrolizumab) were enriched with Lachnoclostridium (Figure 2; Table 1).71